Summit Creek Advisors LLC Acquires 146 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Summit Creek Advisors LLC boosted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 0.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 47,808 shares of the company’s stock after purchasing an additional 146 shares during the period. Medpace comprises approximately 2.1% of Summit Creek Advisors LLC’s investment portfolio, making the stock its 22nd biggest position. Summit Creek Advisors LLC’s holdings in Medpace were worth $15,883,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. R Squared Ltd bought a new stake in Medpace during the fourth quarter worth $30,000. SBI Securities Co. Ltd. bought a new stake in Medpace during the fourth quarter worth $31,000. Stone House Investment Management LLC bought a new stake in Medpace during the third quarter worth $33,000. Jones Financial Companies Lllp lifted its stake in Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after purchasing an additional 110 shares during the last quarter. Finally, Lindbrook Capital LLC lifted its stake in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after acquiring an additional 29 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Up 1.4 %

Shares of NASDAQ:MEDP opened at $324.23 on Monday. The firm has a market cap of $9.88 billion, a P/E ratio of 25.67, a P/E/G ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 12-month low of $302.01 and a 12-month high of $459.77. The business has a fifty day simple moving average of $337.72 and a 200 day simple moving average of $339.77.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, equities research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird increased their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.